Servier Acquires Shire Oncology Business For $2.4bn
Executive Summary
French pharma Servier takes step to meet its strategic ambition of becoming a global player in oncology by acquiring Shire's cancer franchise for $2.4bn
You may also be interested in...
In A Record Year For US FDA Approvals, Pfizer Came Out On Top
FDA’s approval teams cleared a total of 65 new molecular entities and novel biologics in 2018, blowing past previous records. Scrip looks at how that breaks down for industry leaders.
Keeping Track Of The US FDA's Final Approvals Of 2018
A roundup of the US FDA's drug approvals in the final weeks of 2018.
Biopharma Quarterly Dealmaking Statistics, Q2 2018
Biopharma financing for the second quarter totaled $12.4 billion, a 25% decrease from Q1 2018. Meanwhile Q2 merger and acquisition deal value reached $101 billion, three-quarters of which came from Takeda's $79 billion takeover of major European player Shire. Alliances – totaling $13.8 billion (a significant decline from the previous quarter's $30.7 billion) – featured large partnerships in the antibody space, the biotechnology industry sector with the highest dollar volume.